Obesity Is a Significant Risk Factor for Prostate Cancer at the Time of Biopsy

Urology

Volumn 72, Issue 5, 2008, Pages 1102-1105

  Freedland, Stephen J ^a,b   Wen, Joanne ^c,d   Wuerstle, Melanie ^c,d   Shah, Amy ^c,d   Lai, Dominic ^c   Moalej, Bita ^c,d   Atala, Christina ^c,d   Aronson, William J ^c,d  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER PATIENT; CANCER SIZE; CONTROLLED STUDY; GLEASON SCORE; HEMODILUTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OBESITY; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SIZE; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; BIOPSY; BODY MASS INDEX; COHORT STUDIES; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MIDDLE AGED; OBESITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 54449101328     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.05.044     Document Type: Article

References (22)

1. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348 (2003) 1625-1638
2. Rodriguez C., Patel A.V., Calle E.E., et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10 (2001) 345-353
3. Gong Z., Neuhouser M.L., Goodman P.J., et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15 (2006) 1977-1983
4. Rodriguez C., Freedland S.J., Deka A., et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 16 (2007) 63-69
5. Wright M.E., Chang S.C., Schatzkin A., et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109 (2007) 675-684
6. Banez L.L., Hamilton R.J., Partin A.W., et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298 (2007) 2275-2280
7. Baillargeon J., Pollock B.H., Kristal A.R., et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103 (2005) 1092-1095
8. Barqawi A.B., Golden B.K., O'Donnell C., et al. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 65 (2005) 708-712
9. Fowke J.H., Signorello L.B., Chang S.S., et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer 107 (2006) 2361-2367
10. Gray M.A., Delahunt B., Fowles J.R., et al. Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res 24 (2004) 2069-2072
11. Ku J.H., Kim M.E., Lee N.K., et al. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 61 (2003) 132-136
12. Werny D.M., Thompson T., Saraiya M., et al. Obesity is negatively associated with prostate-specific antigen in US men, 2001-2004. Cancer Epidemiol Biomarkers Prev 16 (2007) 70-76
13. Dahle S.E., Chokkalingam A.P., Gao Y.T., et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 168 (2002) 599-604
14. Hammarsten J., and Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39 (2001) 151-158
15. Freedland S.J., Terris M.K., Platz E.A., et al. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology 66 (2005) 108-113
16. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
17. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270 (1993) 860-864
18. Freedland S.J., Platz E.A., Presti Jr. J.C., et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 175 (2006) 500-504
19. Remzi M., Fong Y.K., Dobrovits M., et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 174 (2005) 1256-1260 ; [discussion:1260-1261]; author reply 1261.
20. Freedland S.J., Grubb K.A., Yiu S.K., et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 174 (2005) 919-922
21. Freedland S.J., Aronson W.J., Kane C.J., et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 22 (2004) 446-453
22. Amling C.L., Riffenburgh R.H., Sun L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22 (2004) 439-445